← Back to Screener
InflaRx N.V. Common Stock (IFRX)
Price$1.20
Favorite Metrics
Price vs S&P 500 (26W)-21.67%
Price vs S&P 500 (4W)31.68%
Market Capitalization$102.18M
All Metrics
Book Value / Share (Quarterly)$0.68
P/TBV (Annual)1.39x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.58
Price vs S&P 500 (YTD)17.16%
Gross Margin (TTM)-3693.72%
Net Profit Margin (TTM)-42170.98%
EPS (TTM)$-0.72
10-Day Avg Trading Volume0.78M
EPS Excl Extra (TTM)$-0.72
EPS (Annual)$-0.80
ROI (Annual)-107.39%
Gross Margin (Annual)-24678.79%
Cash / Share (Quarterly)$0.76
Revenue Growth QoQ (YoY)-80.75%
ROA (Last FY)-82.65%
Revenue Growth TTM (YoY)-62.46%
EBITD / Share (TTM)$-0.75
ROE (5Y Avg)-60.62%
Operating Margin (TTM)-35401.52%
Cash Flow / Share (Annual)$-0.58
P/B Ratio1.77x
P/B Ratio (Quarterly)1.39x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1159.42x
Net Interest Coverage (TTM)-13.98x
ROA (TTM)-53.18%
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)4.13x
Quick Ratio (Quarterly)3.88x
3-Month Avg Trading Volume0.51M
52-Week Price Return23.48%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.68
P/S Ratio (Annual)2512.33x
Asset Turnover (Annual)0.00x
52-Week High$1.94
EPS Excl Extra (Annual)$-0.80
CapEx CAGR (5Y)4.20%
Tangible BV CAGR (5Y)-11.74%
26-Week Price Return-17.69%
Quick Ratio (Annual)3.88x
13-Week Price Return18.63%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)4.13x
Enterprise Value$86.387
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-26.92%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-155545.52%
Cash / Share (Annual)$0.76
3-Month Return Std Dev69.21%
Net Income / Employee (TTM)$-1
ROE (Last FY)-109.81%
Net Interest Coverage (Annual)-5.86x
EPS Basic Excl Extra (Annual)$-0.80
Receivables Turnover (TTM)0.02x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.72
ROI (TTM)-67.54%
P/S Ratio (TTM)1164.82x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.68
Price vs S&P 500 (52W)-6.35%
Year-to-Date Return19.80%
5-Day Price Return17.48%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-48.80%
Net Profit Margin (Annual)-155587.38%
Month-to-Date Return35.29%
Cash Flow / Share (TTM)$-0.86
EBITD / Share (Annual)$-0.74
Operating Margin (Annual)-164539.45%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-59.62%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.72
P/TBV (Quarterly)1.39x
P/B Ratio (Annual)1.39x
Inventory Turnover (TTM)0.71x
Pretax Margin (TTM)-42151.56%
Book Value / Share (Annual)$0.68
Price vs S&P 500 (13W)17.94%
Beta1.68x
Revenue / Share (TTM)$0.00
ROE (TTM)-68.47%
52-Week Low$0.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.07
4.07
4.07
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IFRXInflaRx N.V. Common Stock | 1164.82x | -62.46% | -3693.72% | — | $1.20 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
InflaRx NV is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and inflammatory diseases. The company's lead candidate, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a, a key inflammatory mediator implicated in multiple disease pathways. Clinical data has demonstrated disease-modifying activity and a favorable safety profile. The company is advancing this platform with plans to address multiple therapeutic indications.